. . "SE - \u0160v\u00E9dsk\u00E9 kr\u00E1lovstv\u00ED" . . "4"^^ . . "4"^^ . "0172-780X" . "RIV/68081740:_____/11:00371948!RIV13-AV0-68081740" . "The aim was to assess the time to first improvement associated with atypical (AAP) and typical (TAP) antipsychotic drugs in patients with early-onset schizophrenia. This study involved a chart review of all schizophrenic patients in our hospital, with selected AAPs and TAPs, between 1997 and 2007 (296 teenage patients, 141 males, 155 females; mean age 16 years). The time to first improvement could be estimated in 258 patients; of these, 195 patients treated with AAPs and 63 patients with TAPs. Most patients were taking risperidone (96), followed by olanzapine (64). The mean time to first improvement was 6,9 days in the AAP group and 5,8 days in the TAP group (p=0,063). The mean time to first improvement was 7,1 days for risperidone, 6,7 days for olanzapine, 6,5 for ziprasidone, 6,1 for quetiapine, 7,4 for clozapine, 5,2 for haloperidol, 5,9 for perphenazine, and 6,0 for sulpiride. Differences among drugs were not significant (p=0.680)."@en . . "1"^^ . . "5" . "The aim was to assess the time to first improvement associated with atypical (AAP) and typical (TAP) antipsychotic drugs in patients with early-onset schizophrenia. This study involved a chart review of all schizophrenic patients in our hospital, with selected AAPs and TAPs, between 1997 and 2007 (296 teenage patients, 141 males, 155 females; mean age 16 years). The time to first improvement could be estimated in 258 patients; of these, 195 patients treated with AAPs and 63 patients with TAPs. Most patients were taking risperidone (96), followed by olanzapine (64). The mean time to first improvement was 6,9 days in the AAP group and 5,8 days in the TAP group (p=0,063). The mean time to first improvement was 7,1 days for risperidone, 6,7 days for olanzapine, 6,5 for ziprasidone, 6,1 for quetiapine, 7,4 for clozapine, 5,2 for haloperidol, 5,9 for perphenazine, and 6,0 for sulpiride. Differences among drugs were not significant (p=0.680)." . . . . . . "32" . "Onset of action of atypical and typical antipsychotics in the treatment of adolescent schizophrenic psychoses"@en . "218394" . . "Dudov\u00E1, I." . "Hrdli\u010Dka, M." . "Onset of action of atypical and typical antipsychotics in the treatment of adolescent schizophrenic psychoses" . . . . . "Zedkov\u00E1, I." . "Onset of action of atypical and typical antipsychotics in the treatment of adolescent schizophrenic psychoses"@en . "schizophrenia; antipsychotics; onset of action"@en . "I, Z(AV0Z70250504), Z(MSM0021620849)" . "Neuroendocrinology Letters" . "Urb\u00E1nek, Tom\u00E1\u0161" . . "RIV/68081740:_____/11:00371948" . "Onset of action of atypical and typical antipsychotics in the treatment of adolescent schizophrenic psychoses" . . "[E491B96D940C]" . "000300543900015" .